Dolutegravir/lamivudine, sold under the brand name Dovato, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. each pill contains 50 mg dolutegravir, as the salt, an integrase strand transfer inhibitor (INSTI), and 300 mg lamivudine, a nucleoside analogue reverse transcriptase inhibitor (NRTI).[4] It is taken by mouth.[4]
It was approved for use in the United States in April 2019,[4][5][6] and in the European Union in July 2019,[7] and again with revisions in June 2022.[7]